

Amendments to the Claims:

No amendments to the claims have been made.

Listing of the Claims:

This listing of the claims replaces all other listings of the claims in the application:

1. (Previously Presented) A dosage form useful in ophthalmic treatment having a predetermined liquid volume of from about 3 to 20 μl , the dosage form being a jet or stream of droplets of treatment fluid, each droplet having an ophthalmologically active compound in suspension or solution and wherein the jet or each droplet of a size sufficient to sustain momentum along a substantially horizontal path 5 cms in length from a discharge velocity of up to 25 m/sec from the delivery device, wherein substantially the entire dosage form is delivered to the target site and where the jet or stream of droplets is a moving volume of liquid droplets, where the volume has a length and diameter that remain substantially unchanged between exiting the delivery device and contacting the target site.
2. (Original) A dosage form according to claim 1 wherein the jet or each droplet has the active compound in aqueous suspension or solution.
3. (Canceled).
4. (Canceled).
5. (Previously Presented) A dosage form according to claim 1 wherein the jet or each droplet has a diameter in the range 100 to 800 μm .
6. (Original) A dosage form according to claim 5 wherein the jet or each droplet has a diameter in the range 200 to 400 μm .
7. (Previously Presented) A dosage form according to claim 1 in which the total volume of treatment fluid does not exceed 10 μl .
8. (Original) A dosage form according to claim 7 in which the total volume of treatment fluid is in the range 3 to 8 μl .
9. (Previously Presented) A method of ophthalmic treatment comprising delivering to an eye a dosage form according to claim 1.
10. (Original) A method according to claim 9 wherein the eye is a human eye.

11. (Previously Presented) A method according to claim 9 wherein the dosage form is directed at a particular site in the eye.
12. (Previously Presented) A method of increasing the ocular bioavailability of ophthalmologically active compound, wherein the compound is provided in suspension or solution in a body of ophthalmic treatment liquid in a dosage form comprising the liquid as a jet and/or stream of droplets, the jet and/or each droplet being of a size sufficient to sustain momentum in transmission from a delivery device to a target site within an eye, the jet and/or droplets having a mean diameter in the range 20 μm to 1000 μm .
13. (Previously Presented) A method according to claim 12 wherein the mean diameter of the jet and/or droplets is in the range 100 μm to 800 μm .
14. (Previously Presented) A method according to claim 12 wherein the total volume of treatment liquid in the dosage form does not exceed 10 μl .
15. (Original) A method according to claim 14 wherein the total volume of treatment liquid in the dosage form is in the range 3 μl to 8 μl .
16. (Previously Presented) A dosage form according to claim 3 wherein the jet or each droplet has a diameter in the range 100 to 800 μm .
17. (Previously Presented) A dosage form according to claim 3 wherein the jet or each droplet has a diameter in the range 200 to 400 μm .
18. (Previously Presented) A dosage form according to claim 17 in which the total volume of treatment fluid does not exceed 10 μl .
19. (Previously Presented) A method of ophthalmic treatment comprising delivering to an eye a dosage form according to claim 8.
20. (Previously Presented) A method according to claim 12 wherein the mean diameter of the jet and/or droplets is in the range of 200 μm to 400 μm .